A Phase 2, Multicenter, Open-Label Study Of Ds-8201A, An Anti-Her2-Antibody Drug Conjugate (Adc) For Her2-Positive, Unresectable And/Or Metastatic Bre
Posted Date: May 15, 2019
- Investigator: Mahmoud Charif
- Type of Study: Drug
Daiichi Sankyo DS8201-A-U201
Criteria:
To Be Eligible To Participate In This Study, Patients Must Have A Certain Type Of Breast Cancer Call
Keywords:
Breast, Breast Cancer, Cancer, Ds8201-A-U201, Phase Ii
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com